148 related articles for article (PubMed ID: 29048666)
1. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.
Zhang G; Gan YH
Oncol Rep; 2017 Nov; 38(5):2657-2666. PubMed ID: 29048666
[TBL] [Abstract][Full Text] [Related]
2. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Meng Z; Jia LF; Gan YH
Oncogene; 2016 May; 35(18):2333-44. PubMed ID: 26279303
[TBL] [Abstract][Full Text] [Related]
3. Activating PTEN by COX-2 inhibitors antagonizes radiation-induced AKT activation contributing to radiosensitization.
Meng Z; Gan YH
Biochem Biophys Res Commun; 2015 May; 460(2):198-204. PubMed ID: 25770423
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
5. AKT activation controls cell survival in response to HDAC6 inhibition.
Kaliszczak M; Trousil S; Ali T; Aboagye EO
Cell Death Dis; 2016 Jun; 7(6):e2286. PubMed ID: 27362804
[TBL] [Abstract][Full Text] [Related]
6. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Urdiciain A; Erausquin E; Meléndez B; Rey JA; Idoate MA; Castresana JS
Int J Oncol; 2019 May; 54(5):1797-1808. PubMed ID: 30864703
[TBL] [Abstract][Full Text] [Related]
7. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
[TBL] [Abstract][Full Text] [Related]
9. Combination of Pan-HDAC Inhibitor and COX-2 Inhibitor Produces Synergistic Anticancer Effects in Human Salivary Adenoid Cystic Cancer Cells.
Zhang GH; Gan YH
Chin J Dent Res; 2019; 22(4):221-227. PubMed ID: 31859282
[TBL] [Abstract][Full Text] [Related]
10. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lee DH; Kim GW; Kwon SH
Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
12. Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma.
Chen H; Shen X; Guo C; Zhu H; Zhou L; Zhu Y; Wang H; Zheng Y; Huang L
Cancer Biother Radiopharm; 2010 Dec; 25(6):713-21. PubMed ID: 21204766
[TBL] [Abstract][Full Text] [Related]
13. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
[TBL] [Abstract][Full Text] [Related]
14. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Huang Z; Xia Y; Hu K; Zeng S; Wu L; Liu S; Zhi C; Lai M; Chen D; Xie L; Yuan Z
J Neurochem; 2020 Jan; 152(2):221-234. PubMed ID: 31390677
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
[TBL] [Abstract][Full Text] [Related]
20. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
